Solriamfetol - Jazz Pharmaceuticals/SK Biopharmaceuticals
Alternative Names: ADX-N05; ARL-N05; JZP-110; SKL-N05; SUNOSI; SunosiLatest Information Update: 13 May 2025
At a glance
- Originator SK Holdings
- Developer Axsome Therapeutics; Jazz Pharmaceuticals plc; SK biopharmaceuticals
- Class Antidepressants; Behavioural disorder therapies; Carbamates; Sleep disorder therapies; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Trace amine-associated receptor 1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hypersomnia
- Phase III Attention-deficit hyperactivity disorder; Binge-eating disorder; Circadian rhythm sleep disorders; Major depressive disorder
- Discontinued Depressive disorders
Most Recent Events
- 05 May 2025 Axsome Therapeutics plans a clinical trial for Attention-deficit hyperactivity disorder (In Adolescents, In children, In infants, In neonates) in 2025
- 02 Apr 2025 Efficacy and adverse events data from a phase III PARADIGM trial in Major depressive disorder released by Axsome Therapeutics
- 02 Apr 2025 Axsome Therapeutics phase-III clinical trials in Major depressive disorder in USA (PO) (NCT06360419)